Scientist II, Assay Operations, Screening Platform Technologies

Benefits

Parental leave

Not verified

Non-birth-parent leave

Not verified

Family-building benefits

• Fertility benefits: Not verified
• Adoption assistance: Not verified
• Surrogacy assistance: Not verified

Mental health support

Not verified

Relocation assistance

Not verified

Childcare support

Not verified

Learning budget

Not verified

Verification

Not verified checked Jun 7, 2026

Salary

$132K-$166K From the posting source checked Jun 20, 2026

401(k) match

Reported from DOL Form 5500 industry filing (not employer-specific)

Was this benefit information wrong? Tell us.

Market context

U.S. role benchmark (BLS OEWS)

$61,842 U.S. median for this role

Projected growth (BLS Employment Projections)

+1.9% - Slower

141% above the BLS role benchmark for operations aggregate.

Matched to SOC 11-1021 - Operations aggregate by role bucket.

Source: U.S. Bureau of Labor Statistics, OEWS, May 2024 and Employment Projections, 2024-2034.

Role

Role function

Operations From the posting source checked Jun 20, 2026

Seniority

Mid From the posting source checked Jun 20, 2026

Schedule

Shift type

Not verified

Weekend work

Not verified

Company

Company stage

Late-stage From the posting source checked Jun 20, 2026

Equity

Offered Verified - SEC 10-K source checked Jun 20, 2026

Application

Cover letter

Not verified

Assessment

Not verified

Deadline

Not stated

Where they hire

State eligibility is not yet verified.

About this role

Scientist II, Assay Operations, Screening Platform Technologies Redwood City, California, United States Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: We are seeking a Scientist II, Assay Operations, Screening Platform Technologies (SPT) to support and scale next-generation cellular screening capabilities for oncology drug discovery. This role will focus on assay operations, screening execution, automation enablement, and assay scale-up to support high-throughput and high-content screening campaigns across early discovery and lead optimization programs. The successful candidate will partner closely with cross-functional collaborators across Discovery Sciences, Cancer Biology, Automation, Data Science, and external partners to establish robust, scalable, and operationally efficient screening workflows. This position is ideal for a scientist with strong experience executing and operationalizing cellular assays who enjoys working at the intersection of biology, automation, and screening infrastructure. In this role, you will support the transfer, optimization, execution, and scaling of cellular assays across multiple screening platforms, helping ensure assays are automation-ready, reproducible, and fit for high-throughput applications. You will

Read the full description at www.revmed.com. FewerJobs shows a preview and links to the original posting.